

## WEST Search History

DATE: Wednesday, January 08, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
	<i>DB=JPAB; PLUR=YES; OP=ADJ</i>		
L8	Patel D.in.	0	L8
	<i>DB=EPAB; PLUR=YES; OP=ADJ</i>		
L7	Patel D.in.	0	L7
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
L6	Patel D.in.	1	L6
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
L5	Patel D.in.	0	L5
	<i>DB=DWPI; PLUR=YES; OP=ADJ</i>		
L4	McCance J.in.	1	L4
L3	Patel D.in. and papillomavirus	0	L3
L2	Patel D.in. and "E6"	0	L2
L1	Patel D.in.	207	L1


END OF SEARCH HISTORY

- ☐ **15:** [Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM.](#) [Related Articles, Links](#)  
Binding and modulation of p53 by p300/CBP coactivators.  
Nature. 1997 Jun 19;387(6635):823-7.  
PMID: 9194565 [PubMed - indexed for MEDLINE]
- ☐ **16:** [Peng YC, Breiding DE, Sverdrup F, Richard J, Androphy EJ.](#) [Related Articles, Links](#)  
AMF-1/Gps2 binds p300 and enhances its interaction with papillomavirus E2 proteins.  
J Virol. 2000 Jul;74(13):5872-9.  
PMID: 10846067 [PubMed - indexed for MEDLINE]
- ☐ **17:** [Somasundaram K, El-Deiry WS.](#) [Related Articles, Links](#)  
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region.  
Oncogene. 1997 Mar 6;14(9):1047-57.  
PMID: 9070653 [PubMed - indexed for MEDLINE]
- ☐ **18:** [Tsuji Y, Moran E, Torti SV, Torti FM.](#) [Related Articles, Links](#)  
Transcriptional regulation of the mouse ferritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity.  
J Biol Chem. 1999 Mar 12;274(11):7501-7.  
PMID: 10066817 [PubMed - indexed for MEDLINE]
- ☐ **19:** [Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, Mansur CP, Band V, Androphy EJ.](#) [Related Articles, Links](#)  
Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.  
J Virol. 1999 Sep;73(9):7297-307.  
PMID: 10438818 [PubMed - indexed for MEDLINE]
- ☐ **20:** [Sedman SA, Hubbert NL, Vass WC, Lowy DR, Schiller JT.](#) [Related Articles, Links](#)  
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity.  
J Virol. 1992 Jul;66(7):4201-8.  
PMID: 1318401 [PubMed - indexed for MEDLINE]

Display	Summary	<input type="checkbox"/>	Show	20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>
Items 1-20 of 437								Page	1	of 22 Next

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Dec 20 2002 16:27:34



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Bo
Search PubMed	for					Go	Clear	
Limits		Preview/Index		History		Clipboard		Details
Display	Abstract	Show: 20	Sort	Send to		Text		

Entrez PubMed

☐ 1: J Virol 1992 Aug;66(8):5100-5[Related Articles, Links](#)

## Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.

PubMed Services

Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM.

Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892.


Related Resources

The E6 oncoproteins encoded by the cancer-associated human papillomaviruses (HPVs) can associate with and promote the degradation of wild-type p53 in vitro. To gain further insight into this process, the ability of HPV-16 E6 to complex with and promote the degradation of mutant forms of p53 was studied. A correlation between binding and the targeted degradation of p53 was established. Mutant p53 proteins that bound HPV-16 E6 were targeted for degradation, whereas those that did not complex HPV-16 E6 were not degraded. Since the HPV-16 E6-promoted degradation involves the ubiquitin-dependent proteolysis pathway, specific mutations were made in the amino terminus of p53 to examine whether the E6 targeted degradation involved the N-end rule pathway. No requirement for destabilizing amino acids at the N terminus of p53 was found, nor was evidence found that HPV-16 E6 could provide this determinant in trans, indicating that the N-terminal rule pathway is not involved in the E6-promoted degradation of p53.

PMID: 1321290 [PubMed - indexed for MEDLINE]

Display	Abstract	Show: 20	Sort	Send to		Text	
---------	----------	----------	------	---------	--	------	--

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Bo
Search PubMed	<input type="checkbox"/> for						Go	Clear
Limits		Preview/Index		History		Clipboard		Details
Display	Summary	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text
Items 1-20 of 437					Page 1 of 22 Next			

Entrez PubMed

☐ 1: [Bernat A, Massimi P, Banks L.](#)

Related Articles, Links

Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins.

J Gen Virol. 2002 Apr;83(Pt 4):829-33.

PMID: 11907332 [PubMed - indexed for MEDLINE]

PubMed Services

☐ 2: [Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ.](#)

Related Articles, Links

The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.

J Virol. 1999 Aug;73(8):6209-19.

PMID: 10400710 [PubMed - indexed for MEDLINE]

☐ 3: [Patel D, Huang SM, Baglia LA, McCance DJ.](#)

Related Articles, Links

The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.

EMBO J. 1999 Sep 15;18(18):5061-72.

PMID: 10487758 [PubMed - indexed for MEDLINE]

Related Resources

☐ 4: [Zimmermann H, Koh CH, Degenkolbe R, O'Connor MJ, Muller A, Steger G, Chen JJ, Lui Y, Androphy E, Bernard HU.](#)

Related Articles, Links

Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53.

J Gen Virol. 2000 Nov;81(Pt 11):2617-23.

PMID: 11038372 [PubMed - indexed for MEDLINE]

☐ 5: [O'Connor MJ, Zimmermann H, Nielsen S, Bernard HU, Kouzarides T.](#)

Related Articles, Links

Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.

J Virol. 1999 May;73(5):3574-81.

PMID: 10196247 [PubMed - indexed for MEDLINE]

☐ 6: [Dorsman JC, Teunisse AF, Zantema A, van der Eb AJ.](#)

Related Articles, Links

The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co-activator family, including the CREB-binding protein CBP and p300.

J Gen Virol. 1997 Feb;78 ( Pt 2):423-6.

PMID: 9018065 [PubMed - indexed for MEDLINE]

- ☐ **7:** [Vousden KH, Vojtesek B, Fisher C, Lane D.](#) Related Articles, Links  
HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53.  
Oncogene. 1993 Jun;8(6):1697-702.  
PMID: 8389035 [PubMed - indexed for MEDLINE]
- ☐ **8:** [Pouponnot C, Jayaraman L, Massague J.](#) Related Articles, Links  
Physical and functional interaction of SMADs and p300/CBP.  
J Biol Chem. 1998 Sep 4;273(36):22865-8.  
PMID: 9722503 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Zhu Q, Yao J, Wani G, Wani MA, Wani AA.](#) Related Articles, Links  
Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis.  
J Biol Chem. 2001 Aug 10;276(32):29695-701.  
PMID: 11340074 [PubMed - indexed for MEDLINE]
- ☐ **10:** [Lipinski KS, Fax P, Wilker B, Hennemann H, Brockmann D, Esche H.](#) Related Articles, Links  
Differences in the interactions of oncogenic adenovirus 12 early region 1A and nononcogenic adenovirus 2 early region 1A with the cellular coactivators p300 and CBP.  
Virology. 1999 Mar 1;255(1):94-105.  
PMID: 10049825 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Crook T, Tidy JA, Vousden KH.](#) Related Articles, Links  
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.  
Cell. 1991 Nov 1;67(3):547-56.  
PMID: 1657399 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Fontaine V, van der Meijden E, ter Schegget J.](#) Related Articles, Links  
Inhibition of human papillomavirus-16 long control region activity by interferon-gamma overcome by p300 overexpression.  
Mol Carcinog. 2001 May;31(1):27-36.  
PMID: 11398195 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Pim D, Banks L.](#) Related Articles, Links  
HPV-18 E6\*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.  
Oncogene. 1999 Dec 9;18(52):7403-8.  
PMID: 10602499 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Fax P, Lehmkuhler O, Kuhn C, Esche H, Brockmann D.](#) Related Articles, Links  
E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP.  
J Biol Chem. 2000 Dec 22;275(51):40554-60.  
PMID: 11006273 [PubMed - indexed for MEDLINE]